- ‘Most Expensive Drug’ Zolgensma facing new challenge after Two Children Died
- Hair loss and sexual dysfunction added to list of symptoms of long-COVID along with fatigue and brain fog
- Merck diabetes drug Sitagliptin was hit by carcinogenic impurities
- CDC relaxes and reiterates its COVID-19 guidance
- How does NOVAVAX solve the dilemma when COVID-19 vaccine sales plummeted by 90%?
- Scientists develop new antibiotic molecule that kills several superbugs
How to predict what vaccinators will still be infected with COVID-19?
How to predict what vaccinators will still be infected with COVID-19? Science, Nature, NEJM common concern…. Mankind’s fight against the new coronavirus is really difficult.
Whenever humans think that they have won victory, they find that they are facing another, more serious problem.
Human pride reached its peak when a highly protective COVID-19 vaccine was developed. Indeed, in less than a year, a vaccine with more than 90% protection was developed, which is indeed amazing.
Countries have introduced an open timetable for achieving “herd immunity”.
But immediately, the new coronavirus used a mutant strain to give humans a heavy blow.
Now, countries no longer mention herd immunity, but believe that “human beings must learn to coexist with the new coronavirus for a long time,” and “individuals should bear their own responsibilities.”
Because even with Pfizer’s mRNA vaccine, the best vaccine at present, the protection against COVID-19 has continued to decline, from 94%-64%-39%—.
On July 29, 2021, health officials in Los Angeles announced that in the first half of July, 26% of patients newly infected with COVID-19 in Los Angeles County were fully vaccinated. To be precise, from July 1 to July 16, 13,598 cases were confirmed in the county, of which 3,592 were vaccinated.
Humans have been unable to completely stop the spread of the new coronavirus.
The key questions now are: How to predict which vaccinators will still be infected with COVID-19?
This issue involves further prevention and intensive vaccination.
On this issue, medical scientists have begun to have preliminary results.
On July 29, 2021, Barney Graham, one of the main contributors to the development of the COVID-19 mRNA vaccine, published an important article in Science, reporting the correlation between the protection induced by mRNA-1273 and the immune response.
In the study, rhesus monkeys were vaccinated with 0.3-100ug of mRNA-1273, and it was found that the peripheral and mucosal antibodies induced by the vaccine were significantly correlated with the vaccination dose.
The vaccinated rhesus monkeys challenged SARS-CoV-2. Vaccination significantly reduced virus replication in the upper and lower respiratory tracts, and this protection was positively correlated with the levels of S protein antibodies and neutralizing antibodies.
The study also found that the antibody titer required to protect the lower respiratory tract is lower than that of the upper respiratory tract. This finding has been repeatedly verified by many previous discoveries that the prevention and treatment of lower respiratory tract infections are prone to upper respiratory tract infections.
The adoption of rhesus IgG inoculated with mRNA-1273 to hamsters can protect hamsters from virus infection.
This research verifies what I have repeatedly emphasized that the core protection of vaccines works through neutralizing antibodies.
Through extremely rigorous design, this research of Science in the laboratory directly proves that the protective power of vaccines against infection is positively correlated with the titers of neutralizing antibodies.
So what about clinical cases?
On July 29, 2021, Nature magazine deliberately interpreted the Israeli study published in the New England Journal of Medicine (NEJM). The title is “A blood marker predicts who gets ‘breakthrough’ COVID”.
We also interpreted this article yesterday. Among the infections among Israeli medical staff, 1,497 fully vaccinated medical staff had 39 cases (0.4%) of breakthrough infections that were confirmed positive by PCR.
The study of Israeli medical staff infected with the Delta mutant strain was published, revealing more information about vaccine changes
Most importantly, the Israeli study found that the neutralizing antibody titers of these breakthrough infection patients were lower than those of uninfected vaccinators; and the viral load (Ct) after infection was inversely proportional to the neutralizing antibody titer.
This study confirmed through clinical studies that the level of neutralizing antibodies can indeed be a biomarker for predicting the protective status of vaccines.
There is increasing evidence that a person’s neutralizing antibody levels can predict whether the person will be infected, because these antibodies prevent SARS-CoV-2 from infecting cells.
However, there is currently no research to provide specific antibody levels related to protection, that is, how high the neutralizing antibody can protect the vaccinated from infection after vaccination. And this is exactly what doctors and scientists are doing.
Let’s also add the Los Angeles epidemic mentioned earlier.
Although from July 1 to July 16, of all newly infected people in Los Angeles, fully vaccinated people accounted for 26%; however, vaccinated people accounted for less than 0.01% of the hospitalized population.
Therefore, even though the vaccine has been unable to prevent the vaccinated person from contracting COVID-19, it can still effectively protect the infected person from developing into a critical condition.
(source:internet, reference only)